financetom
Business
financetom
/
Business
/
ChipMOS Technologies to Repurchase up to $10.7 Million Shares
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
ChipMOS Technologies to Repurchase up to $10.7 Million Shares
Jan 21, 2025 4:39 AM

07:07 AM EST, 01/21/2025 (MT Newswires) -- ChipMOS Technologies ( IMOS ) said Tuesday that it has authorized a share repurchase program totaling up to 350 million New Taiwan dollars ($10.7 million).

The company said it plans to buy back up to 10 million shares on the Taiwan Stock Exchange, which is 1.4% of its issued capital.

The repurchase will take place between NT$21.18 per share and NT$35 per share, and the buyback will continue even if the stock price falls below this range, the company said.

The program is set to run from Jan. 22 to March 21.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Spain's High Court upholds temporary ban on Worldcoin iris-scanning venture
Spain's High Court upholds temporary ban on Worldcoin iris-scanning venture
Mar 11, 2024
MADRID (Reuters) -Spain's High Court on Monday upheld a temporary ban on Worldcoin's iris-scanning venture, in the latest blow to a project that has sparked privacy concerns in several countries. The court said the safeguarding of the public interest must prevail, dismissing an appeal by Worldcoin's owners. Co-founded by OpenAI CEO Sam Altman in 2019, Worldcoin aims to create a...
Lexeo Therapeutics' Q4 Net Loss Narrows; Cash Runway Extended to 2027 -- Shares Jump Pre-Bell
Lexeo Therapeutics' Q4 Net Loss Narrows; Cash Runway Extended to 2027 -- Shares Jump Pre-Bell
Mar 11, 2024
09:06 AM EDT, 03/11/2024 (MT Newswires) -- Lexeo Therapeutics ( LXEO ) reported a Q4 net loss Monday of $0.86 per diluted share, narrowing from a loss of $8.86 a year earlier. Three analysts polled by Capital IQ expected a loss of $0.71. The clinical-stage company reported no revenue for the quarter ended Dec. 31, matching the average estimate of...
HSBC to hire almost 50 bankers for startup, venture lending in US
HSBC to hire almost 50 bankers for startup, venture lending in US
Mar 11, 2024
NEW YORK, March 11 (Reuters) - HSBC ( HSBC ) is planning to recruit about 50 more bankers in its U.S. commercial bank to lend to startup companies, mainly in the technology and healthcare sectors, according to a senior executive. HSBC ( HSBC ) hired about 40 people from Silicon Valley Bank after the latter lender failed a year ago....
Lexicon Pharmaceuticals Q4 Net Loss Widens, Revenue Rises; to Resubmit NDA for Sotagliflozin; Shares Gain Pre-Bell
Lexicon Pharmaceuticals Q4 Net Loss Widens, Revenue Rises; to Resubmit NDA for Sotagliflozin; Shares Gain Pre-Bell
Mar 11, 2024
09:05 AM EDT, 03/11/2024 (MT Newswires) -- Lexicon Pharmaceuticals ( LXRX ) shares rose by more than 9% in premarket trading on Monday after it reported Q4 results and said it would resubmit a new drug application for sotagliflozin as an adjunct to insulin therapy for patients with type 1 diabetes and chronic kidney disease. Lexicon reported a Q4 net...
Copyright 2023-2026 - www.financetom.com All Rights Reserved